Baxter Vaccines AG
Industriestraße 67
A-1221 Wien




  Find:      

Research Center

Baxter Vaccines has two research centers: one is located in Orth an der Donau near Vienna/Austria and the other one in Columbia/Maryland/USA. Our scientists are focused on the development of new vaccines to prevent a broad spectrum of infectious diseases in infants, children, and adults based on our proprietary technology platforms. In addition, these technologies – like the conjugate and the Vero cell platform - are used to improve the safety and efficacy of existing vaccines.


Conjugate vaccines: making the connection to prevent infection

Children in the first two years of life are particularly vulnerable to infection: their immune system is not yet prepared to fight off diseases. Many of these diseases are caused by bacteria covered with protective surface capsules of long-chain sugars called polysaccharides. Polysaccharide vaccines can provide protection against some of these bacterial infections, but they are usually ineffective in the immature immune systems of children under two years of age. Conjugate vaccines couple or link these sugars to a carrier protein molecule. This polysaccharide-protein conjugate is able to stimulate a strong immune response to the polysaccharide moiety of the conjugate. Existing Haemophilus influenza type b (Hib) vaccines, which have worked remarkably well in infants, use this technology. At Baxter, we use it for our vaccines against meningococcal, streptococcal or pneumococcal infections. The experts in our US research center are developing unique protein carriers for each of our bacterial vaccines to provide you with the best vaccine for long-term protection.


Vero cell technology: purity that counts

Continuous cell lines have a number of advantages such as excellent growth characteristics, simple media requirements and the consistency of the material. Furthermore, vaccines produced with this method in contrast to egg-based technologies are free from egg or avian protein, free from adventitious agents, contain no thiomersal and also no antibiotic additives. The safety of Vero cells for the production of biologicals has been demonstrated by the safe administration of about 100 million doses over 15 years worldwide in nearly 60 countries. The Vero cell line technology is an ideal platform for the production of a variety of different viruses such as Influenza virus, tick borne encephalitis, Hepatitis A virus, (recombinant) vaccinia virus, Ross River virus, Japanese encephalitis virus, St. Louis encephalitis virus and West Nile virus.